Loading clinical trials...
Loading clinical trials...
A Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib (ONO/GS-4059) in Combination With Other Targeted Anti-cancer Therapies in Subjects With B-cell Malignancies
Conditions
Interventions
Tirabrutinib
Idelalisib
+2 more
Locations
15
United States
Georgetown University Medical Center
Washington D.C., District of Columbia, United States
Indiana University Health Goshen Center for Cancer Care
Goshen, Indiana, United States
Oregon Health and Science University
Portland, Oregon, United States
CHRU de Lille, Hopital Claude Huriez
Lille, France
Hopital Saint Eloi
Montpellier, France
Chu Haut Leveque
Pessac, France
Start Date
June 16, 2015
Primary Completion Date
September 25, 2024
Completion Date
September 25, 2024
Last Updated
June 17, 2025
NCT07349849
NCT06590961
NCT05780034
NCT03125577
NCT03050190
NCT06351527
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions